We are live on ! Find out more
Cambridge Investment Research Advisors

Cambridge Investment Research Advisors Portfolio holdings

AUM $44.6B
1-Year Est. Return 28.94%
This Fund
S&P 500
This Quarter Est. Return
+10.37%
1 Year Est. Return
+28.94%
3 Year Est. Return
+82.62%
5 Year Est. Return
+90.41%
10 Year Est. Return
+293.66%
AUM
$32.9B
AUM Growth
+$3.25B
Cap. Flow
+$735M
Cap. Flow %
2.23%
Top 10 Hldgs %
20.5%
Holding
3,797
New
302
Increased
1,702
Reduced
1,533
Closed
189

Sector Composition

Rank Sector Weight
1 Technology 11.86%
2 Financials 5.23%
3 Consumer Discretionary 3.7%
4 Communication Services 2.92%
5 Industrials 2.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TNYA icon
3601
Tenaya Therapeutics
TNYA
$164M
$7K ﹤0.01%
12,186
+1,000
+9% +$509
VRCA icon
3602
Verrica Pharmaceuticals
VRCA
$83.5M
$6K ﹤0.01%
1,150
WOLF icon
3603
Wolfspeed
WOLF
$1.64B
$6K ﹤0.01%
+15,684
New +$35.8K
MBRX icon
3604
Moleculin Biotech
MBRX
$4.06M
$4K ﹤0.01%
511
SCWO icon
3605
374Water
SCWO
$44.6M
$3K ﹤0.01%
1,000
XAIR icon
3606
Beyond Air
XAIR
$6.14M
$2K ﹤0.01%
29
TALKW
3607
DELISTED
Talkspace Inc Warrant
TALKW
$1K ﹤0.01%
10,550
SCD.RT
3608
DELISTED
LMP Capital and Income Fund Inc. Rights (expiring July 11, 2025)
SCD.RT
$1K ﹤0.01%
+14,985
New +$1.69K
ABSI icon
3609
Absci
ABSI
$1.62B
-10,330
Closed -$26K
ACNB icon
3610
ACNB Corp
ACNB
$660M
-4,926
Closed -$203K
AFG icon
3611
American Financial Group
AFG
$12.1B
-18,796
Closed -$2.47M
AGEN
3612
Agenus
AGEN
$315M
-13,712
Closed -$21K
AGNG icon
3613
Global X Aging Population ETF
AGNG
$89.8M
-11,568
Closed -$362K
AGO icon
3614
Assured Guaranty
AGO
$3.35B
-14,812
Closed -$1.3M
AIO
3615
Virtus Artificial Intelligence & Technology Opportunities Fund
AIO
$921M
-97,615
Closed -$2.01M
AMPH icon
3616
Amphastar Pharmaceuticals
AMPH
$858M
-13,790
Closed -$400K
AMRN
3617
Amarin Corp
AMRN
$299M
-627
Closed -$6K
AMZY icon
3618
YieldMax AMZN Option Income Strategy ETF
AMZY
$248M
-22,803
Closed -$366K
APLY icon
3619
YieldMax AAPL Option Income Strategy ETF
APLY
$117M
-14,292
Closed -$216K
APTV icon
3620
Aptiv
APTV
$10.2B
-3,501
Closed -$208K
ASGI
3621
abrdn Global Infrastructure Income Fund
ASGI
$781M
-28,330
Closed -$521K
ASH icon
3622
Ashland
ASH
$3.36B
-4,597
Closed -$273K
OPTU
3623
Optimum Communications Inc
OPTU
$228M
-10,000
Closed -$27K
AVDL
3624
DELISTED
Avadel Pharmaceuticals
AVDL
-72,216
Closed -$565K
AVO icon
3625
Mission Produce
AVO
$1.15B
-127,770
Closed -$1.34M

Similar funds

Cambridge Investment Research Advisors's Q2 2025 Portfolio in Review

As of Q2 2025, Cambridge Investment Research Advisors held 3,797 positions worth $32.9B, up 11% from $29.6B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Cambridge Investment Research Advisors's Q2 2025 filing shows 302 new, 1,702 increased, 1,533 reduced and 189 closed positions. Its largest new stake was JPMorgan Mortgage-Backed Securities ETF: 707,098 shares worth $35.5M. The largest sale was Invesco Ultra Short Duration ETF, an estimated $52.3M.

By sector, the portfolio is most concentrated in Technology at 12% of assets, up from 11% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Cambridge Investment Research Advisors's largest Q2 2025 buy was JPMorgan Mortgage-Backed Securities ETF: 707,098 shares worth $35.5M.
  • Cambridge Investment Research Advisors added most to State Street SPDR Portfolio S&P 500 ETF in Q2 2025, an estimated $67M increase.
  • Cambridge Investment Research Advisors's biggest Q2 2025 reduction was Invesco Ultra Short Duration ETF, cutting an estimated $52.3M.
  • Cambridge Investment Research Advisors fully exited MicroSectors FANG+ ETNs due Jan 8 2038 in Q2 2025, selling an estimated $8.22M.
  • Cambridge Investment Research Advisors's ten largest holdings make up 20% of its $32.9B portfolio in Q2 2025.
  • Cambridge Investment Research Advisors opened 302 new positions and closed 189 in Q2 2025.
  • Cambridge Investment Research Advisors's portfolio value rose 11% quarter-over-quarter to $32.9B.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2025, filed 31 Jul 2025.